Key Takeaway: The article discusses long-term data from an expanded access program for Arimoclomol in adults with Niemann-Pick disease type C (NPC) in the USA. Presented at the Society for Inherited Metabolic Disorders (SIMD), the findings highlight the drug's potential benefits in a real-world context. This data contributes to understanding Arimoclomol's effectiveness and safety.
Price reaction · baseline $4.87 (2024-04-15T15:30:00.000Z) · hit during market hours · clean, no other ZVRA news in the window
day 0 close · peak
-1.7%
Market Sentiment Analysis
POSITIVE FACTORS
Long-term data from expanded access program shows promise.
Real-world setting provides valuable insights into Arimoclomol's efficacy.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Medical Publications and Presentations
Arimoclomol in adults with NPC in a real-world setting: Long-term data from an expanded access program in the USA
Society for Inherited Metabolic Disorders (SIMD) - 04/15/2024
Download PDF
Download PDF
Frequently Asked Questions
What is Arimoclomol used for?
Arimoclomol is used to treat Niemann-Pick disease type C (NPC).
What does the expanded access program entail?
The expanded access program allows patients to access Arimoclomol outside of clinical trials.
Where was the data presented?
The data was presented at the Society for Inherited Metabolic Disorders (SIMD).
What is the significance of real-world data?
Real-world data provides insights into the drug's effectiveness and safety in everyday settings.